
Alicyclobacillus used to be the problem (for fruit juice manufacturers). Now is the solution (for CRISPR-diagnostics). Read the MIT News on STOPCovid, the first FDA-approved test based on CRISPR. Here’s an extract.
Continue readingAlicyclobacillus used to be the problem (for fruit juice manufacturers). Now is the solution (for CRISPR-diagnostics). Read the MIT News on STOPCovid, the first FDA-approved test based on CRISPR. Here’s an extract.
Continue readingMay 7th 2020 will be remembered as a good day for CRISPR. Yesterday the first CRISPR/Cas-based test received Emergency Use Authorization from the U.S. Food and Drug Administration. The Sherlock SARS-CoV2 kit works by programming a CRISPR enzyme to detect the coronavirus genetic signature, providing results in about one hour. Quickly and cheaply indeed, as the materials for one test cost about $6.
Continue readingSay hello to CARMEN: a massively multiplexed, Cas13-based technology for nucleic acid detection, out yesterday in Nature. Its name stands for Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids, and it allows us to test many amplified samples for the presence of many viral sequences by using miniaturized detection reactions that self-organize in a microwell array. Sars-Cov2 included.
Continue readingResearchers from all the life sciences are turning their attention to the pandemic, and the CRISPR community is no exception. The latest CRISPR Journal‘s editorial presents a few of the projects that are showing promise, and others are probably going on. Kevin Davies and Rodolphe Barrangou also comment on the cancellation or postponement of several key conferences in the next few months due to Covid-19, especially the CRISPR 2020 meeting in Paris. They applaud all the scientists who are battling this disease in myriad ways and promise: we’ll meet again.
CRISPR holds promise for the treatment of cancer and inherited disorders, as you know, but what about infectious diseases? It can do many useful things indeed, according to this review by Jeffrey Strich and Daniel Chertow, published in the Journal of Clinical Microbiology.
Continue readingPCR, POC testing, CRISPR diagnostics, immunoassays. Many tests much confusion. Thankfully, Nature Biotechnology and the Financial Times bring some clarity on fast, portable tests to curb coronavirus pandemic.
Continue readingHopefully, CRISPR-based diagnostics will make an early debut amid COVID-19 outbreak. But what about a CRISPR prophylactic strategy to combat coronaviruses? The proof of concept is here, in bioRxiv, but it will be deployed in the next pandemic if we are lucky. It’s called PAC-MAN, like the videogame, stands for Prophylactic Antiviral CRISPR in huMAN cells, and comes from the Stanley Qi Lab.
Continue readingDo you remember Sherlock? The CRISPR-based platform was heralded in Science as a new generation of low cost diagnostic tests with single-base specificity, easy to use even when oubreaks occur in remote areas. The good news is that Feng Zhang and colleagues are sharing a research protocol, applicable to purified RNA, that may inform the development of a Sherlock test for COVID-19. For more information, visit the McGovern Institute website.